Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression &#8805;50% on first-line pembrolizumab.

Yamaguchi, Ou; Kaira, Kyoichi; Shinomiya, Shun; Mouri, Atsuto; Hashimoto, Kosuke; Shiono, Ayako; Miura, Yu; Akagami, Tomoe; Imai, Hisao; Kobayashi, Kunihiko; Kagamu, Hiroshi

Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.

Yamaguchi, Ou; Kaira, Kyoichi; Shinomiya, Shun; Mouri, Atsuto; Hashimoto, Kosuke; Shiono, Ayako; Miura, Yu; Akagami, Tomoe; Imai, Hisao; Kobayashi, Kunihiko; Kagamu, Hiroshi.

Afiliação

Yamaguchi O; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Kaira K; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Shinomiya S; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Mouri A; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Hashimoto K; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Shiono A; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Miura Y; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Akagami T; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Imai H; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Kobayashi K; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
Kagamu H; Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.

Thorac Cancer ; 12(3): 304-313, 2021 02.

Article em En | MEDLINE | ID: mdl-33185333

Assuntos

Anticorpos Monoclonais Humanizados/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Antígeno B7-H1/metabolismo; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Doenças Pulmonares Intersticiais/tratamento farmacológico; Neoplasias Pulmonares/tratamento farmacológico; Idoso; Idoso de 80 Anos ou mais; Anticorpos Monoclonais Humanizados/farmacologia; Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Carcinoma Pulmonar de Células não Pequenas/patologia; Feminino; Humanos; Doenças Pulmonares Intersticiais/patologia; Neoplasias Pulmonares/patologia; Masculino; Pessoa de Meia-Idade; Prognóstico; Estudos Retrospectivos

Palavras-chave

Immune checkpoint inhibitor; interstitial lung disease; non-small cell lung cancer; pembrolizumab; pneumonitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doenças Pulmonares Intersticiais / Carcinoma Pulmonar de Células não Pequenas / Anticorpos Monoclonais Humanizados / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Thorac Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google